CDISC, a global, open, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata, has named five highly qualified individuals that will add invaluable expertise to the CDISC board of directors (BoD) for a three-year term beginning this month (2013–2016): Dr. Carolyn Compton, Michael Glickman, Dr. Douglas Peddicord, Stephen Pyke and John Speakman.
Carolyn Compton, M.D. and Ph.D., is the current president and CEO of the Critical Path Institute (C-Path), which is partnered with CDISC through the Coalition For Accelerating Standards and Therapies (CFAST) and other initiatives through which the CDISC Alzheimer’s disease and tuberculosis standards were developed. Compton served for 15 years as the director of gastrointestinal pathology at the Massachusetts General Hospital, as a professor of pathology at Harvard Medical School and the chair of pathology and pathologist-in-chief at McGill University Health Center. Before taking on her current role at C-Path, she served as director of the Office of Biorepositories and Biospecimen Research and the executive director of the Cancer Human Biobank Project at the National Cancer Institute.
Michael Glickman, MSE, is the founder and president of Computer Network Architects, through which he has worked with hundreds of healthcare organizations and has experience with every popular EHR system currently available. He has over 45 years of experience in the computer industry, and during the last 35 years has specialized in the unique problems of systems integration in healthcare. His HIT expertise includes EHRs, Continuity of Care Record (CCR) integration, server consolidation, including “clinically reliable” business continuity/disaster recovery (BC/DR), enterprise PACS via enterprise SANs for all modalities, LAN/WAN/MAN technologies, voice convergence including unified communications (UC), patient care devices (PCD) and Health Information Exchange (HIE). Glickman was a founding member of the HL7 Working Group and currently serves as chair of the U.S. Technical Advisory Group to ISO TC215 Health Informatics.
Douglas Peddicord, Ph.D., serves as executive director of the Association of Clinical Research Organizations (ACRO), which has been a major supporter of CDISC and the move toward clinical data standards to improve the quality and efficiency of clinical trials. He is also president of Washington Health Strategies Group, which provides a full range of strategic consulting, government affairs and association management services to healthcare organizations. His particular areas of expertise include health information technology and medical privacy, clinical trials, medical informatics and Medicare coverage and payment policy.
Stephen Pyke serves as the vice president of quantitative sciences at GlaxoSmithKline, with 17 years experience in the pharmaceutical industry. In his current role, Pyke leads a multidisciplinary group of 600 quantitative scientists spanning statistics and programming, clinical pharmacology modeling and simulation, epidemiology, genetics and computational biology. He has also held a number of honorary positions including past-chair and board member of Statisticians in the Pharmaceutical Industry (PSI), and is currently vice president and council member of the Royal Statistical Society.
John Speakman serves as senior director of research information technology for the New York University (NYU) Langone Medical Center. He joined NYU in July 2012. Speakman collaborates with the research community both at NYU and beyond with the goal of connecting people and technology to further the research mission of the Center in basic science, clinical trials, investigator-initiated and sponsored projects. Previously, he served at the National Cancer Institute (NCI) as chief program officer for the Center for Biomedical Informatics and Information Technology. Speakman was re-elected to the CDISC board this year after serving in 2012.